SCHEMBL5163531

SCHEMBL5163531

CN(C)c1c(C(=O)N(C)c2ccccc2)c(=O)n(C)c2cccc(C(F)(F)F)c12

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.54
▸ KMT2A Q03164 3/20 0.54
▸ PGR P06401 1/20 0.54
▸ HDAC4 P56524 1/20 0.52
▸ SRC P12931 1/20 0.46
▸ POLQ O75417 3/20 0.41
▸ GPBAR1 Q8TDU6 1/20 0.39
▸ MAP3K5 Q99683 1/20 0.38
▸ SGMS2 Q8NHU3 5/20 0.37
▸ POLB P06746 2/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ NR1H3 Q13133 2/20 0.36
▸ PABPC1 P11940 1/20 0.35
▸ SGMS1 Q86VZ5 2/20 0.35
▸ SLC16A1 P53985 1/20 0.35
▸ TP53 P04637 1/20 0.34
▸ NR1H2 P55055 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5165191 0.84 KMT2A (0.58) MEN1KMT2APGRHDAC4SRC
SCHEMBL5164446 0.83 MEN1 (0.57) MEN1KMT2APGRHDAC4SRC
SCHEMBL7721592 0.81 MEN1 (0.46) MEN1KMT2APGRHDAC4SRC
SCHEMBL5165920 0.81 HDAC4 (0.61) MEN1KMT2APGRHDAC4SRC
SCHEMBL6999935 0.81 HDAC4 (0.63) MEN1KMT2APGRHDAC4SRC
SCHEMBL7722456 0.79 HDAC4 (0.39) MEN1KMT2APGRHDAC4MAP3K5
SCHEMBL10670006 0.79 KMT2A (0.74) MEN1KMT2APGRHDAC4SRC
SCHEMBL7245512 0.77 HDAC4 (0.69) MEN1KMT2APGRHDAC4SRC
SCHEMBL5164782 0.77 HDAC4 (0.58) MEN1KMT2APGRHDAC4SRC
SCHEMBL10678687 0.75 MEN1 (0.68) MEN1KMT2APGRHDAC4SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1224172-B1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS ACTIVE BIOTECH AB (SE) 2007-04-04 — — EP disclosed
EP-1224172-A1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS Active Biotech AB (SE) 2002-07-24 — — EP disclosed
US-6395750-B1 Includes laquinimod, N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxo-quinoline-3-carboxamide and its salts; breat or prostate cancer ACTIVE BIOTECH AB (SE) 2002-05-28 — — US disclosed
WO-2001030758-A1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS ACTIVE BIOTECH AB (SE) 2001-05-03 — — WO disclosed
Send feedback